Seeking Alpha

SMaturin

SMaturin
Send Message
View as an RSS Feed
View SMaturin's Comments BY TICKER:
Latest  |  Highest rated
  • Stability Of The European Union (21) August 28, 2013 To November 8, 2013 [View instapost]
    Agree, WT.

    Still watching (TUR) and (EWS).

    Roller coasters worth a ride, but TUR will be greatly affected by events in neighboring Syria. It is not a happy border at the moment.

    http://bit.ly/17EztKT

    http://reut.rs/17EztKU

    http://abcn.ws/17EztKX

    http://bit.ly/17EztL1
    Sep 4, 2013. 11:43 AM | 3 Likes Like |Link to Comment
  • Stability Of The European Union (21) August 28, 2013 To November 8, 2013 [View instapost]
    Politics and DemoPublican silliness aside, I am not so sure the correction has run its course.

    I would agree with TB that waiting to see whether we actually start bombing another Muslim country makes sense at the moment.

    Another bumper sticker I got recently: http://bit.ly/1dGAto1
    Sep 4, 2013. 10:37 AM | 6 Likes Like |Link to Comment
  • Axion Power Concentrator 265: September 04: 10Q Filing For Q2; Two Axion Forbes Articles; John Petersen On PIPE Mechanics & Incentives [View instapost]
    The article does not seem to explain whose "carbon enhanced capacitive lead-acid batteries" are being used. Is this going to use the UltraBattery that ALABC has crowed about? Or is somebody else copying the PbC design?

    Controlled Power Technologies does not seem to be making batteries, only starter motors, turbos and electronics: http://bit.ly/177TYAI

    Faurecia is about emmissions tech: http://bit.ly/1dGbZLA

    Who will supply the 48V lead carbon battery system? Ford?
    Sep 4, 2013. 08:30 AM | 5 Likes Like |Link to Comment
  • Swine Flu AND Medical News Concentrator August 28, 2013 To November 8, 2013 [View instapost]
    Smith agrees.

    http://seekingalpha.co...
    Sep 4, 2013. 08:18 AM | 2 Likes Like |Link to Comment
  • QC#262, September 3, 2013 [View instapost]
    Hard to encrypt that missile cone sticking up out of the silo on the right.

    I can see it even without my tinfoil goog Glasses!

    I never realized they were such a pastoral agency.
    Sep 3, 2013. 04:57 PM | 3 Likes Like |Link to Comment
  • QC#262, September 3, 2013 [View instapost]
    Is that the NSA bunker?
    Sep 3, 2013. 04:19 PM | 3 Likes Like |Link to Comment
  • Swine Flu AND Medical News Concentrator August 28, 2013 To November 8, 2013 [View instapost]
    IT will be a roller coaster short-term. But I am in it for the long-term, when tirasemtiv gets to market for ALS and mysthenia gravis. That could be a five year plus horizon.

    The omecamtiv data for acute heart failure are just icing on the cake for me. These data clearly support moving into Phase III trials using the higher doses from the Phase II study.
    Sep 3, 2013. 04:01 PM | 3 Likes Like |Link to Comment
  • Swine Flu AND Medical News Concentrator August 28, 2013 To November 8, 2013 [View instapost]
    Here is a good but rather technical explanation of why the news and Adam F have no clues about the value of this drug. This was a dose finding study, and dyspnea relief was not the most relevant endpoint in severely ill hospitalized patients in acute heart failure:

    http://bit.ly/17KzMaR

    >>
    The patients enrolled in ATOMIC-AHF had a history of heart failure and reduced injection fraction [sic, should be "ejection fraction," the measure of how much of the blood volume of the left ventricle gets pushed into the aorta when it contracts] within injection fraction less than or equal to 40%. They were all hospitalized for acute heart failure requiring intravenous therapy with dyspnea due to heart failure at rest or minimal incursion despite the administration of an intravenous diuretic.

    In addition they do have to have elevations in their B&P or MT pro-B&P. While this study was a Phase II dose finding study, we also investigated and evaluated some efficacy primary endpoint was selected to be dyspnea symptom response through the first 48 hours. We have a multiple secondary efficacy endpoints selected, as well as evaluation of PK, PD from this eco sub-study [sic, echocardiogram, not "eco"].

    And now I'd like to present the actual results of the trial. 613 patients were enrolled in ATOMIC-AHF and they had characteristics consistent with patients who were admitted for acute heart failure with reduction in systolic function. They had a high prevalence of ischemic heart disease as well as multiple other co-morbidities.

    In addition patients enrolled in this trial had excellent background therapy for their chronic heart failure and despite an exclusion criteria which we excluded patients with clinical ACS or acute coronary syndromes.

    We had over half of the patients with troponins that were above the upper reference limit. In addition, the NT-proBNP in the 9,000 to 10,000 range is among the highest observed in any acute heart failure study. The primary efficacy endpoint consisted of evaluation of the dyspnea response using a seven level Likert scale. Ranging from markedly worsen to markedly improved.

    A patient was considered responder if they met the following criteria which was that they were minimally moderately or markedly better at six hours and moderately or markedly better at 24 and 48 hours without worsening of heart failure or death for any cost by 48 hours. So these are the primary results of the initial analysis of the ATOMIC-AHF trial. And in this figure you can see an increase in the dyspnea response rate from 42% in cohort 1 up to 51% in cohort 3 this 51% represents a 23% increase in treatment effect compared to the pulled placebo group. group to all of the omecamtiv mecarbil cohorts was not statistically significant with the P value of 0.33. A pre-specified supplementary analysis to the primary endpoint evaluated the paring of the placebo with the omecamtiv mecarbil from the same cohort.

    Within this analysis we can see that the placebo response rate among patients in cohort three was 37%, while among the omecamtiv mecarbil treated patients in cohort three the response rate was 51%. This represents a 41% improvement in treatment effect in the omecamtiv mecarbil group in the third cohort with a nominal p value of 0.03.
    <<
    Sep 3, 2013. 03:32 PM | 5 Likes Like |Link to Comment
  • Swine Flu AND Medical News Concentrator August 28, 2013 To November 8, 2013 [View instapost]
    Added some more CYTK this afternoon at firesale prices.

    Thanks, Adam F.
    Sep 3, 2013. 03:16 PM | 4 Likes Like |Link to Comment
  • Axion Power Concentrator 264: August 30: 10Q Filing For Q2; Two Axion Forbes Articles; John Petersen On PIPE Mechanics & Incentives [View instapost]
    VW and HTL,

    The Manchester Terrier was actually bred to be a ratter: http://bit.ly/1dLpxGp

    My mom has one as a pet, and it is extremely protective, loyal and obedient to her. Dad has to play second fiddle to the dog. ;-)

    I had squirrels gnawing a hose for the LPG tank on a barbecue once. Cayenne and tinfoil solved the problem. Capsicum pepper spray would likely work as well.
    Sep 3, 2013. 11:20 AM | 3 Likes Like |Link to Comment
  • Swine Flu AND Medical News Concentrator August 28, 2013 To November 8, 2013 [View instapost]
    Japanese health ministry wants H7N9 vaccine to be made, but no mention yet which producers will do so.

    http://bit.ly/175wImX
    Sep 3, 2013. 11:03 AM | 5 Likes Like |Link to Comment
  • Swine Flu AND Medical News Concentrator August 28, 2013 To November 8, 2013 [View instapost]
    Also on wsj.com

    http://on.wsj.com/15vm77G
    Sep 3, 2013. 11:01 AM | 3 Likes Like |Link to Comment
  • Axion Power Concentrator 264: August 30: 10Q Filing For Q2; Two Axion Forbes Articles; John Petersen On PIPE Mechanics & Incentives [View instapost]
    Is that on the same menu as okra and turnip smoothies?
    Sep 3, 2013. 07:37 AM | 4 Likes Like |Link to Comment
  • QC#261 [View instapost]
    He does not give any time frame regarding the taper effect on closed end physical funds.

    When has he not said "buy physical!" ?
    Sep 1, 2013. 09:21 PM | 4 Likes Like |Link to Comment
  • QC#261 [View instapost]
    The question in my mind is whether the threat of "Taper" will lead to a retreat from risk assets into GTU, PHYS, PSLV, and CEF?
    Sep 1, 2013. 08:58 PM | 3 Likes Like |Link to Comment
COMMENTS STATS
2,305 Comments
840 Likes